We want to transform healthcare by developing novel vaccines that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative vaccines for a healthier world
Advancing groundbreaking vaccines through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge vaccines to address some of the worst and most impactful diseases.
Our vaccine candidates aim at bringing hope to millions by preventing infectious diseases and treating cancer, saving lives, and fostering resilient communities.
Latest news
ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines
Hørsholm, Denmark, 16 October 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, announces that a term sheet has been entered with Serum Institute of India Private Limited (“SIIPL”), the world’s largest vaccine manufacturer. Upon execution of…
Read moreNotice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)
N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on 21…
Read moreExpreS2ion to present in upcoming investor events
Hørsholm, Denmark, 10 September 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events, including Investing in Life Science: From Seed to Success and a Danish Stock seminar for institutional investors.
Read more